Salt form of a human histone methyltransferase EZH2 inhibitor
Kevin Wayne Kuntz, Woburn, MA (US); Kuan-Chun Huang, Andover, MA (US); Hyeong Wook Choi, Andover, MA (US); Kristen Sanders, Gilmanton, NH (US); Steven Mathieu, Andover, MA (US); Arani Chanda, Malden, MA (US); and Francis Fang, Andover, MA (US)
Assigned to Epizyme, Inc., Cambridge, MA (US); and Eisai R&D Management Co., Ltd., Tokyo (JP)
Filed by Epizyme, Inc., Cambridge, MA (US); and Eisai R&D Management Co., Ltd., Tokyo (JP)
Filed on Sep. 29, 2022, as Appl. No. 17/936,555.
Application 17/936,555 is a continuation of application No. 17/032,432, filed on Sep. 25, 2020, granted, now 11,491,163.
Application 17/032,432 is a continuation of application No. 16/270,752, filed on Feb. 8, 2019, granted, now 10,821,113, issued on Nov. 3, 2020.
Application 16/270,752 is a continuation of application No. 15/837,390, filed on Dec. 11, 2017, granted, now 10,245,269, issued on Apr. 2, 2019.
Application 15/837,390 is a continuation of application No. 15/199,522, filed on Jun. 30, 2016, granted, now 9,872,862, issued on Jan. 23, 2018.
Application 15/199,522 is a continuation of application No. 14/394,431, granted, now 9,394,283, issued on Jul. 19, 2016, previously published as PCT/US2013/036193, filed on Apr. 11, 2013.
Claims priority of provisional application 61/624,215, filed on Apr. 13, 2012.
1. A polymorph of N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl) methyl)-5-(ethyl (tetrahydro-2H-pyran-4-yl) amino)-4-methyl-4′-(morpholinomethyl)-[1,1′-biphenyl]-3-carboxamide hydrobromide, wherein the polymorph exhibits an X-ray powder diffraction pattern having characteristic peaks expressed in degrees 2-theta at 10.9±0.2 degrees, 20.9±0.2 degrees, and 25.7±0.2 degrees 2-theta.